<DOC>
	<DOC>NCT02718378</DOC>
	<brief_summary>The current study is designed as a phase Ib multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of E4 in healthy men after daily oral administration for 28 days.</brief_summary>
	<brief_title>Evaluation of Safety and Efficacy of Estetrol in Healthy Men</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male, age between 40 and 70 years (both inclusive); Good physical and mental health as judged by the Investigator determined by medical history, physical examination (including prostate palpation), clinical laboratory, vital signs and ECG recording; Body mass index between ≥ 18.5 and ≤ 30.0 kg/m2; Normal prostatespecific antigen (PSA) value (&lt; 3.0 ng/mL); Nonvasectomized men must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study medication. Men who have been vasectomized less than 4 months prior to study start must follow the same restrictions as nonvasectomized men; Men must agree not to donate sperm from the first dose until 90 days after the last dose; Ability to communicate well with the Investigator and to comply with the requirements of the entire study; Willing to give informed consent in writing. Any clinically significant abnormality following review of medical history, laboratory results, physical examination and ECG at screening as judged by the Investigator; Conditions or disorders that might affect the absorption, distribution, metabolism or excretion of any of the study drugs; Previous use of steroids within: 8 weeks for oral preparations 4 weeks for transdermal preparations Any time for injections; Contraindications for steroids or estetrol; Prostate hyperplasia or micturition problems that suggest the presence of prostate hyperplasia; Presence of an active acute or chronic infection, including syphilis, HIV or viral hepatitis B and/or C (or previously treated); Treatment for any major psychiatric disorder in the previous 12 months or use of antidepressant medication before screening; Hypersensitivity to the active substances or to any of the excipients of the investigational product or placebo therapy; Use of probiotics (as present in dairy products, fortified foods etc.) during the 3 months before screening and during the clinical study; Use of one or more of the following medications: Antihypertensive drugs Present use or use within 30 days before the start of the study drug of the following drugs: aprepitant, bosentan, armodafinil, phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine, glucocorticoids, topiramate, felbamate, rifampicin, clobazamechinacea; vemurafenib, nonnucleoside reverse transcriptase inhibitors, griseofulvin, ketoconazole, and herbal remedies containing Hypericum perforatum Any medication (including overthecounter products) within 14 days before first dosing except for occasional nonsteroidal antiinflammatory drugs (NSAIDs; e.g. ibuprofen); paracetamol is not permitted Use of antibiotics; Administration of any other investigational drug within 3 months before first dosing; Loss of more than 400 mL blood during the 3 months before screening, e.g. as a blood donor, or intention to donate blood in the 3 months after completing the study; Subjects with a history of (within 12 months) alcohol or drug abuse or with a positive result at screening, for tests of: alcohol intake drug abuse; Currently smoking or smoked within the last 6 months before screening.</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>randomized</keyword>
</DOC>